Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESRRG | P62508 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 8/20 | 0.43 |
| ▸ | RORC | P51449 | 2/20 | 0.43 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6575820 | 0.81 | GRIA4 (0.51) | ESRRGL3MBTL1CNR2RORCCNR1 | |
| SCHEMBL6761055 | 0.79 | CA1 (0.40) | L3MBTL1MEN1KMT2ATBXAS1TSHR | |
| SCHEMBL6565154 | 0.78 | SMN1; SMN2 (0.50) | L3MBTL1MEN1KMT2ATBXAS1TSHR | |
| SCHEMBL6573845 | 0.77 | GRIA4 (0.41) | MEN1KMT2ACNR2 | |
| SCHEMBL6763729 | 0.77 | NR1H2 (0.43) | ESRRGCNR2 | |
| SCHEMBL6626226 | 0.74 | MEN1 (0.61) | L3MBTL1MEN1KMT2ATBXAS1NPC1 | |
| SCHEMBL6563391 | 0.72 | MEN1 (0.54) | L3MBTL1MEN1KMT2ATBXAS1TSHR | |
| SCHEMBL14719879 | 0.72 | MEN1 (0.77) | L3MBTL1MEN1KMT2ARAB9A | |
| SCHEMBL15754219 | 0.72 | L3MBTL1 (0.64) | L3MBTL1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL6762192 | 0.72 | GRIA4 (0.40) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040147612-A1 | Sulfonamide derivatives | DAVISON JOSHUA ZWICK (US) | 2004-07-29 | — | — | US | disclosed |
| EP-1409452-A1 | SULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2004-04-21 | — | — | EP | disclosed |
| WO-2002098846-A1 | SULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2002-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147612-A1 | Sulfonamide derivatives | GRIN1, GRIN2A, GRIA1 | ESRRG 817/4885L3MBTL1 4647/4885MEN1 4050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.